Editas Medicine Inc.

12/12/2024 | Press release | Distributed by Public on 12/12/2024 15:00

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.